Heart Conditions — Expert Guides

AI in Cardiology: What It Means for Your Heart, and What It Cannot Do

June 14, 2026

Key Points

Artificial intelligence is already being used in cardiology, quietly and carefully, in ways that are genuinely improving patient care.
AI does not replace your cardiologist. It gives them better tools, more time, and sharper information to make decisions with you.
From reading ECGs to analysing intracoronary imaging, planning complex procedures, and assessing heart valves, AI is being applied across almost every area of heart medicine.
Neural networks are already shortening the time taken to analyse complex imaging, making procedures faster and more accurate.
The goal is the same as it has always been: getting the right treatment to the right patient.

If you have heard the term artificial intelligence, or AI, mentioned in the context of medicine, and been unsure whether to find it exciting or unsettling, you are not alone. The term carries a lot of weight in public conversation, and not always in reassuring directions.

So let us be clear about something from the outset. The AI being developed and applied in cardiology is not about replacing doctors, or making decisions by algorithm, or removing the human relationship at the heart of medicine.

It is about giving cardiologists better tools. Tools that can process more information more quickly, spot patterns that are difficult for the human eye to detect, and help ensure that every patient benefits from the full weight of accumulated medical knowledge, not just the experience of the individual clinician in front of them.

As one of the leading figures applying AI to cardiovascular research and daily clinical practice, my view is clear. AI is here to help improve workflow, and that efficiency creates more face-to-face time with patients. Not less.

What Do We Actually Mean by AI in Cardiology?

AI is a broad term that encompasses several different technologies. In cardiology, the most relevant are machine learning, where a computer learns to recognise patterns by analysing large amounts of data, and deep learning, a more sophisticated version that can analyse complex images such as heart scans with remarkable accuracy.

Neural networks, modelled loosely on the structure of the human brain, sit at the heart of many of these systems. They are capable of identifying patterns in imaging data at a speed and consistency that no human analyst could match.

These are not futuristic concepts. They are already in use in hospitals and catheterisation laboratories around the world, often in ways that patients would not notice. They run quietly in the background, helping clinicians interpret information faster and more accurately than would otherwise be possible.

Speaking at the 2026 European Association of Percutaneous Cardiovascular Interventions Summit in Munich, I described AI as transforming cardiology at a pace that is genuinely unprecedented, having been at the forefront of applying machine learning to some of the largest datasets in coronary disease research, including the SYNTAX trial, which followed 1,800 patients for 10 years.

But alongside that enthusiasm, I was equally clear about the caution required. To trust an AI estimation more than clinical expertise, we have to be certain it has been proven in outcomes studies. Progress, but never at the expense of safety. That balance, genuine excitement tempered by rigorous caution, is precisely what patients should expect from the doctors leading this field.

Where Is AI Already Making a Difference?

The clearest way to understand where AI sits in modern cardiology is to follow the journey a patient takes, from the moment a problem is first suspected through to the treatment decision and beyond. At every stage of that journey, AI is already at work.

How AI Works in Cardiology

From data to clinical decision

Data Input

ECG readings, CT scans, echo images, blood tests, and your medical history are gathered, the raw information about your heart.

Neural Network

Trained on millions of examples, the AI identifies patterns in that information that are invisible to the human eye.

Analysis

Risk scores, measurements, plaque characterisation, and predictions are produced in seconds rather than hours.

Your Cardiologist

Reviews the AI output alongside clinical judgement and makes the final decision with you.

AI informs. Your cardiologist decides.

Stage 1: before you ever reach a specialist

AI is already working before most patients know they have a problem. Tools trained on millions of ECG recordings can now detect patterns associated with heart attacks, irregular rhythms, and structural heart disease with accuracy that matches experienced clinicians. Some of these tools are built into smartwatches and portable devices, bringing ECG analysis into patients’ own homes.

In resource-limited parts of the world, AI-powered digital stethoscopes and portable devices are allowing patients in communities without specialist cardiologists to be assessed and triaged to a standard that previously required a fully equipped hospital. A patient who would once have waited months to see a specialist, or never seen one at all, can now have their heart rhythm analysed, their valve function assessed, and their cardiovascular risk stratified using tools that fit in a small case.

This matters more than almost any other application of AI in medicine. The burden of cardiovascular disease falls most heavily on low- and middle-income countries, precisely the places with the fewest cardiologists, the least access to imaging equipment, and the longest distances between patients and the hospitals that could help them.

AI does not fix those structural problems. But it does mean that a community health worker in a rural clinic, equipped with a smartphone and a portable ECG device, can now make a triage decision that would previously have required a trained cardiologist. The technology does not replace the specialist. It extends their reach to places they cannot physically be.

Stage 2: investigating your heart

Once a problem is suspected, you will be referred for tests. This is where AI is already embedded most deeply in clinical practice.

Computed tomography coronary angiography, or CTCA, uses X-ray technology to produce detailed images of the coronary arteries. AI and machine learning are now being used to interrogate these datasets far beyond what conventional analysis could achieve. The presence, extent, and characteristics of plaque can be assessed with a granularity that helps your clinical team make better-informed decisions before you ever reach the procedure room.

The echocardiogram, the ultrasound of the heart, is one of the most widely used diagnostic tools in cardiology. Machine learning algorithms can now assist in assessing heart valve function with impressive accuracy. What is particularly striking is that the benefit is greatest for less experienced operators. A sonographer early in their training, using an AI-assisted system, can achieve diagnostic accuracy that would previously have required years of experience.

In some centres, robotic echocardiography systems guided entirely by AI are now acquiring images without a sonographer needing to hold the probe at all, opening up access to high-quality cardiac imaging in areas where specialist staff are scarce.

Stage 3: planning your procedure

When treatment is needed, AI is transforming how your clinical team prepares. Computational fluid dynamics, or CFD, combines your imaging data with mathematical modelling of blood flow to simulate how blood actually moves through your coronary arteries, and how different treatment strategies will change that flow. The procedure can effectively be planned and rehearsed virtually before it is performed.

This goes further still with what might be called a digital twin: a precise virtual replica of your specific heart and coronary anatomy, built from your own imaging data. Different treatment approaches can be tested on this model, complications anticipated, and the optimal strategy identified, all before you enter the operating theatre.

I am actively collaborating with Professor Peter Barlis and his team, and at the Peter Barlis Laboratory we have been using AI to simulate blood flow at bifurcation points, the branching junctions where blockages are most technically challenging to treat, with the goal of improving precision and safety for each individual patient.

“Where is AI most useful in cardiology? Preplanning. Planning is everything.”

Prof. Patrick Serruys, Interventional Cardiologist

Stage 4: in the procedure room

Once you are in the catheterisation laboratory, AI is present in real time. Intracoronary imaging techniques such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS) look inside the coronary arteries during procedures and generate large amounts of imaging data. Neural networks can now analyse this data at a speed that would have been unimaginable a decade ago. They characterise plaque, identify high-risk features, and predict the result of a stenting procedure, all in the time it takes to complete the procedure itself.

AI is also reading the angiogram in real time as your cardiologist works, automatically measuring the degree of narrowing, the length of the blockage, and the appropriate stent size. A randomised clinical trial has shown that AI-guided angiography analysis produces results comparable to the most detailed imaging techniques available. This is AI genuinely in the room, providing an objective second opinion at the most critical moment of the procedure.

Stage 5: choosing your treatment

Perhaps the most directly relevant application of AI for patients is in the decision between stenting and bypass surgery. Rather than a broad population-based recommendation, machine learning models applied to the SYNTAX trial dataset were able to distinguish meaningfully between patients who looked similar on the surface but whose predicted outcomes differed significantly depending on which treatment they received.

Research Spotlight

The blood tests that turned out to matter more than anyone realised

When the SYNTAX trial dataset was analysed using machine learning, two findings stood out. C-reactive protein, a blood test that measures inflammation, and haemoglobin levels, which reflect anaemia, both emerged as powerful predictors of long-term outcomes after heart treatment. Neither had featured prominently in conventional cardiology risk scoring.

A further surprise was gamma-glutamyl transferase, a liver enzyme routinely measured in blood tests but not traditionally associated with heart outcomes. The machine learning model identified it as a significant predictor of 10-year outcomes. I was initially sceptical, but the finding held up in external validation across thousands of additional patients. It turns out this enzyme is a marker of oxidative stress, which does have a meaningful impact on plaque build-up and heart function.

These are not exotic tests. They are measurements taken routinely in almost every patient undergoing cardiac assessment. What AI revealed is that information we were already collecting was telling us more than our existing models were capturing.

What This Means for You

Not one answer for everyone. A different answer for each person.

When the machine learning model was applied to individual patients in the SYNTAX dataset, it identified three distinct groups. For some patients, stenting and bypass surgery were predicted to produce essentially the same outcome, genuine clinical equipoise, where patient preference should play a larger role in the decision. For others, it predicted a clear advantage for bypass surgery. And for a smaller group, stenting was the stronger option.

The goal is not to have an algorithm make the decision. It is to give your heart team better information so that when they sit down with you to discuss your options, the recommendation they make is as precisely tailored to your specific situation as possible.

The quieter wins: less paperwork, more conversation

One of the less dramatic but genuinely meaningful applications of AI in medicine is the reduction of administrative burden. Cardiologists, like all doctors, spend a significant portion of their working day on documentation, dictating notes, completing forms, and reviewing records. AI-assisted tools can take notes during consultations, generate clinical summaries, and help organise information so that less time is spent on administration and more time is available for the patient in the room.

There is also a more personal dimension that is rarely discussed: what AI means for the conversation between you and your doctor. When a cardiologist tells you that an AI algorithm has analysed your scan, or that a machine learning model has helped inform the recommendation for stenting over surgery, you deserve to understand what that means and who is ultimately responsible for the decision.

The answer to that last question has not changed. Your cardiologist is responsible. AI informs; it does not decide. The shared decision between you and your clinical team remains at the centre of your care, and no algorithm changes that.

AI and Your Heart Team

One of the most important things to understand about AI in cardiology is that it does not work in isolation, and it was never designed to. The Heart Team model, where your cardiologist and cardiac surgeon review your case together before making a recommendation, is precisely where AI adds the most value. The scoring tools, the imaging analysis, the risk predictions, all of this information is brought to that meeting, discussed, and weighed alongside things that no algorithm can measure: your preferences, your circumstances, your priorities.

Traditionally, a Heart Team meeting has centred on reviewing your angiogram images on a screen, measuring segments of arteries by eye, and debating the best approach based on accumulated experience.

AI is transforming this in a concrete and visible way. Machine learning can now process your coronary imaging data and assess your arterial anatomy with a speed and precision that was not previously possible, producing accurate measurements of vessel segments, identifying the location and extent of blockages, and predicting how different stenting or bypass strategies are likely to perform in your specific anatomy.

Extended reality takes this further still. Building on work developed at the CORRIB Research Centre at the University of Galway, coronary imaging data can now be converted into a three-dimensional hologram that the entire Heart Team can explore together before any procedure begins. Rather than looking at flat images on a screen, your cardiologist and cardiac surgeon can examine a three-dimensional model of your coronary arteries, rotate it, fly through it, and measure it in precise detail. The intervention can be planned virtually before you have entered the operating theatre or the catheterisation laboratory.

This has been demonstrated in real surgical cases, including the planning of complex multi-vessel bypass operations, where holographic measurements guided decisions about which vessels to bypass and which grafts to use.

The conversation that follows is still deeply human. The decision that emerges from it is still yours to make, with your team, together. What AI and extended reality change is the quality and precision of the information on the table when that conversation happens.

What AI Cannot Do, and Why That Matters

It is just as important to be clear about the limitations of AI in cardiology as it is to acknowledge its promise. Leading clinicians in this field are the first to make this point.

AI models are trained on data from past patients. They are powerful at identifying patterns within that data, but they cannot handle what they have never seen, and they require retraining as medical knowledge evolves. A model trained predominantly on data from one type of patient population may perform less well when applied to a different population. This is why external validation across diverse groups is essential before any AI tool is used in clinical practice.

There are also important questions about data privacy, about the transparency of AI decision-making, and about ensuring that the benefits of these tools are available equitably, not just to patients in well-resourced healthcare systems.

One of the most honest concerns in this field is what researchers call the black box problem. Many AI models can tell you what conclusion they have reached, but cannot easily explain how they reached it. A neural network that identifies a high-risk plaque on a CT scan may do so with impressive accuracy, but it cannot always show the clinician its reasoning in the way that a human expert can. Different AI platforms applied to the same imaging data can sometimes reach different conclusions.

Understanding where AI is reliable, where it is uncertain, and where it requires human oversight is not a weakness of the technology. It is the essential work of responsible implementation.

Perhaps most importantly: AI does not know you. It does not know that you are frightened, or that you have a strong preference for a less invasive approach, or that your recovery will be shaped by circumstances that no dataset could capture. That knowledge belongs to your cardiologist, your cardiac surgeon, and your clinical team. The human relationship at the centre of medicine, the conversation, the trust, the shared decision, is not something that any algorithm replaces.

What This Means for You as a Patient

If you are a cardiac patient today, or if someone you love is, the most reassuring thing I can say is this. The cardiologists caring for you are not waiting passively for AI to arrive. They are actively using and evaluating these tools, carefully, with the same rigour they apply to any new treatment or technology.

The ECG you had may have been read with the assistance of an AI algorithm. The scan images of your heart may have been processed by software that flags findings for a radiologist or cardiologist to review. The risk assessment your team carried out before recommending treatment may have drawn on scoring tools developed using machine learning on large patient datasets. The intracoronary images taken during your procedure may have been analysed by neural networks that helped guide exactly where and how a stent was placed.

None of this happened instead of your doctor’s judgement. It happened alongside it, giving them better information, faster, so that the decision they made with you was as well-informed as possible.

That is what AI in cardiology is for. Not to alarm. Not to replace. Simply to help the people caring for your heart do their jobs a little better, and to give you, as a patient, the benefit of everything medicine has learned.

Conclusion

AI in cardiology is not a glimpse of some distant future. It is already in the room with you, in the ECG software that flagged your rhythm, in the imaging analysis that helped your team measure your arteries, in the risk scoring that informed your treatment plan. None of it has changed who is responsible for your care, and none of it has removed the human conversation at the heart of medicine.

What it has done is sharpen the information your cardiologist works with, shorten the time between question and answer, and extend the reach of expert care to places it could not previously go. The realistic futures, as I often put it, are arriving faster than anyone anticipated. The question is no longer whether AI will reshape how we care for patients with heart disease. It already has. The question is how thoughtfully, how rigorously, and how equitably we carry that forward.

References

Serruys PW. AI in Cardiovascular Imaging and Interventions: Boon or Bane? Presented at the EAPCI Summit, Munich, February 2026. Reported by TCTMD.
Ninomiya K, Serruys PW et al. Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization? Journal of the American College of Cardiology, 2023;82:2113 to 2124.
Serruys PW et al. 10 Years of SYNTAX: Closing an Era of Clinical Research After Identifying New Outcome Determinants. JACC: Asia, 2023.
American Heart Association Scientific Advisory on AI in Cardiovascular Medicine, 2025.

Aortic Stenosis: When the Heart’s Gateway Narrows

June 10, 2026June 7, 2026

The aortic valve opens and closes 100,000 times a day. When it begins to narrow, the heart pays the price. Here is how aortic stenosis develops, how it is diagnosed, and how modern treatment, from open surgery to TAVR, restores flow.

Patent Foramen Ovale (PFO): What the “Hole in the Heart” Finding Really Means

June 4, 2026June 4, 2026

Key Points

A patent foramen ovale (PFO) is a small opening between the two upper chambers of the heart, present in roughly one in four adults, that simply did not seal after birth the way it usually does.
The vast majority of PFOs cause no symptoms and are found by chance. For most people, a PFO needs no treatment at all.
In a smaller group of patients, particularly those who have had a cryptogenic stroke (a stroke with no identified cause), a PFO may be the route by which a small clot crossed from the right to the left side of the heart and travelled to the brain.
In selected patients after a cryptogenic stroke, PFO closure (a minimally invasive catheter procedure) lowers the risk of a further stroke and is now supported by strong trial evidence.
Migraine with aura has a well-recognised association with PFO, though the relationship is complex, and closing a PFO for migraine alone is not currently standard practice.

A patent foramen ovale is one of those findings that can sound alarming when it is first mentioned. A hole in the heart, discovered on an echocardiogram, is not a phrase anyone wants to hear. And yet for most people who have one, it is entirely inconsequential. It requires no treatment, no monitoring, no change to how you live, and nothing you need to act on.

The reassurance I give most patients with a PFO is simple. You have a structural variation that around one in four adults share. In the vast majority of cases it is a finding rather than a diagnosis, something noted and filed, not something that needs managing.

Where it does become clinically relevant, mainly in the setting of an unexplained stroke in a younger person, is a separate and important conversation. But that conversation starts from a very different clinical picture than an incidental echo finding in someone who is otherwise well.

What Is a PFO?

Normal Circulation Before Birth

Before birth, the lungs are not yet doing their job. Rather than breathing, the baby receives oxygen-rich blood from the placenta. To bypass the lungs while they are still at rest, the circulation of every developing baby includes a small opening between the two upper chambers of the heart, called the foramen ovale. Blood passes straight through it from the right side to the left, skipping the lungs entirely.

At birth, the first breath opens the lungs, blood flow through them rises sharply, and the pressure in the left upper chamber climbs above that of the right. This change in pressure presses a small flap of tissue against the opening and seals it. In most people this seal becomes permanent over the first months of life, as the two layers of tissue gradually fuse.

What is a Patent Foramen Ovale?

A small unsealed opening in the wall between the upper chambers of the heart

Patent Foramen Ovale

An unsealed flap between the upper chambers, present in about 1 in 4 adults

~25%

of adults have a PFO, and most never know

Echo

Usually found by chance on an echocardiogram

Closure

Considered in selected stroke patients

heartmatters.com, patient education

When It Doesn’t Close

In around 25 to 27% of adults, roughly one in four, this fusion does not fully happen. The flap stays unsealed, leaving a potential channel between the two upper chambers that can open at moments of raised pressure on the right side of the heart, such as straining, coughing, or bearing down. This is a patent foramen ovale.

It is not a defect in the usual sense of the word. The heart formed normally, and the closure process simply did not finish. It causes no structural problem, no pressure abnormality, and no effect on how the heart works in the great majority of people who have one.

How Is a PFO Found?

Most PFOs are discovered by chance, on an echocardiogram done for another reason, such as looking into palpitations, a murmur, or as part of a stroke assessment. On a standard echocardiogram a PFO can be hard to see directly. A bubble study, in which a small amount of agitated saline is injected into a vein while you gently bear down, shows the PFO by revealing tiny bubbles crossing from the right chamber to the left. A transoesophageal echocardiogram gives the most detailed picture of a PFO’s size and shape.

Does It Actually Matter? The Context Question

The Incidental PFO, by Far the Most Common Situation

An incidental PFO, found in someone who has not had a stroke, has no neurological symptoms, and is otherwise well, needs no treatment. No blood thinners, no antiplatelet medicine beyond anything already needed for another reason, no closure procedure, and no restriction on activities including diving in most cases (high-altitude diving is a more nuanced discussion worth having with your cardiologist).

The most important thing I tell patients in this situation is that the finding does not change your risk in any way that matters clinically. One in four adults has one, and most go their whole lives without ever knowing.

PFO and Cryptogenic Stroke, the Association That Matters

About 30% of ischaemic strokes have no clear cause even after thorough investigation. These are called cryptogenic strokes. In younger patients who have had a cryptogenic stroke, a PFO is found more often than chance alone would explain, which suggests that in these individuals the PFO may have been the route through which the stroke happened.

The likely mechanism is called paradoxical embolism. A small clot forms in the venous system, often in the leg veins, travels to the right side of the heart, and crosses through the PFO into the left side at a moment of raised pressure, from where it can travel to the brain. This can happen without any obvious sign of a deep vein clot beforehand.

When a brain scan shows several small areas of stroke in different regions, suggesting clots arriving from a single source, a PFO assessment becomes particularly important. This is one reason prolonged heart monitoring for atrial fibrillation often goes hand in hand with a PFO assessment after a cryptogenic stroke. Both conditions can produce a similar pattern of stroke and need to be carefully told apart.

Three landmark randomised trials (RESPECT, CLOSE, and REDUCE) showed that closing a PFO in carefully selected patients after a cryptogenic stroke significantly lowers the risk of another stroke compared with antiplatelet medicine alone. This evidence has made PFO closure a standard recommendation for suitable patients after a cryptogenic stroke, typically those under 60 with a sizeable PFO and no other identified cause for the stroke.

Migraine With Aura

There is a well-documented link between PFO and migraine with aura. A PFO is more common in people who have migraine with aura than in the general population, and some people report fewer migraines after a PFO is closed. However, the trial evidence for closing a PFO specifically to treat migraine is mixed, and closure is not currently recommended for migraine with aura in someone who has not had a stroke. This remains an area of active research, and it is a reasonable thing to ask your cardiologist about if it affects you.

What PFO Closure Involves

PFO closure is a catheter-based procedure, with no open heart surgery involved. A thin tube is passed through a vein in the groin and guided up into the right upper chamber of the heart. With the help of echocardiography and X-ray guidance, a small device shaped like two discs is positioned across the opening, with one disc resting on each side of the wall. Over the following months, the body’s own tissue grows over the device and seals the opening permanently.

The procedure usually takes 30 to 60 minutes under sedation or light general anaesthesia, and most people go home the next day. Antiplatelet medicine is taken for a period afterwards, typically about six months, while the device becomes covered by the heart’s own lining. The long-term results are excellent, and device-related complications are very uncommon.

1 in 4
adults has a patent foramen ovale, making it one of the most common structural variations of the heart. For the great majority it is entirely harmless and needs no treatment.
American Heart Association

Clinical Situation	Typical Approach	Why
Incidental PFO, no stroke, no symptoms	Reassurance, no treatment needed	One in four adults has one; the risks of closing it outweigh any benefit
Cryptogenic stroke, under 60, no other cause found	PFO closure, strongly considered	Trial evidence shows a meaningful drop in further strokes
Cryptogenic stroke, over 60	Individualised, blood thinners often preferred	Other possible mechanisms more likely; benefit of closure less clear
Migraine with aura, no stroke history	No closure, not standard practice	Evidence not yet sufficient; trials ongoing
Decompression illness in divers	Individualised assessment	A careful, case-by-case discussion with a specialist

The most important conversation I have with patients who have a PFO is about context. The finding can be the same in two people. The significance can be entirely different. Context is everything.

Prof. Peter Barlis, Interventional Cardiologist

Questions Worth Asking at Your Next Appointment

My PFO was found by chance. Do I need any treatment, monitoring, or change to how I live?
I have had a stroke with no identified cause. Is my PFO likely to have been involved, and could I be a candidate for closure?
What do the size and shape of my PFO mean for my risk? Are all PFOs the same?
I dive recreationally. Does having a PFO change my risk, and should I adjust how I dive?
I have migraine with aura. Is there a link with my PFO, and is closure something I should consider?

Heart Matters Resource

When in Doubt, Get Checked Out

If you have been told you have a PFO and are unsure what it means for you, particularly if you have had a neurological event, a cardiology review to put the finding in context is the right next step.

Read: When in Doubt, Get Checked Out →

Conclusion

A patent foramen ovale is perhaps the cardiac finding that most needs to be put in context. In the great majority of people who have one, and a quarter of all adults do, it is entirely harmless, needs no intervention, and is nothing you need to act on.

In a carefully defined group of patients, those who have had a cryptogenic stroke at a younger age with no other identifiable cause, closing a PFO is a worthwhile step with strong evidence behind it. The procedure is safe, effective, and minimally invasive.

The key, in the end, is context. The very same finding can mean completely different things depending on the clinical picture in which it is discovered. Your cardiologist’s role is to place that finding in its proper frame, and where that frame is reassurance, the reassurance should be complete and confident.

What is a Muscle Bridge?

June 2, 2026May 31, 2026

Key Points

A myocardial bridge, often just called a muscle bridge, is a common and usually harmless variant present from birth, where a short stretch of a coronary artery dips down and runs through the heart muscle instead of sitting on the surface. Most people who have one will never know and never need treatment.
In a minority of people, a bridge can cause genuine symptoms, most often chest pain or tightness brought on by exertion or stress. These patients deserve to be taken seriously rather than reassured by default.
A standard angiogram often underestimates a bridge. Confirming whether a bridge is actually causing symptoms usually needs more detailed assessment, including intravascular ultrasound and specialised stress testing.
Most symptomatic bridges are managed well with medication, usually beta-blockers or calcium channel blockers. A small, carefully selected group with severe, persistent symptoms may benefit from an operation called surgical unroofing.
A large 2026 study from Stanford, published in the European Heart Journal, found that for this selected group, surgical unroofing produced lasting relief from angina five years later, with a low complication rate.

You have a muscle bridge. Many people hear that sentence for the first time lying on an angiogram table, nod along, and leave none the wiser. It is rarely explained in much depth, partly because for most people it carries no consequence at all, and partly because the few it does affect need a longer conversation than a results appointment allows.

A myocardial bridge is one of the most common variations in human heart anatomy. The overwhelming majority cause no symptoms, need no treatment, and carry no meaningful risk. For a smaller group of people, though, a bridge can be a real and treatable cause of angina, and telling those two groups apart is what good assessment is for.

This article explains what a muscle bridge actually is, why most are harmless, how the troublesome minority are identified, and what the newest evidence says about treating them.

What a Myocardial Bridge Actually Is

The coronary arteries, the vessels that supply blood to the heart muscle itself, normally run along the outer surface of the heart, sitting on top like rivers on a landscape. A myocardial bridge is a stretch where one of these arteries takes a short detour and tunnels down through the heart muscle before surfacing again on the other side.

The band of muscle lying over the tunnelled segment is the “bridge.” The buried portion of artery is sometimes called the tunnelled segment. It is present from birth, which means a bridge is a variation in how the heart formed rather than something that develops, wears in, or is caused by lifestyle. Around 97% of bridges occur in the same vessel, the left anterior descending artery, which runs down the front of the heart.

Diagram comparing a normal coronary artery running along the heart surface with a myocardial bridge, where the artery dips down through the heart muscle and is squeezed with each heartbeat. — In a normal artery, blood flows freely along the heart’s surface. In a myocardial bridge, the artery dips down and runs through the heart muscle for a stretch, and the overlying muscle squeezes that segment with each heartbeat.

The reason a bridge can matter comes down to mechanics. Every time the heart contracts, the muscle squeezes. If a segment of artery is buried inside that muscle, it gets squeezed too, narrowing with each beat. The heart does most of its own blood supply during the relaxation phase between beats, and in a bridge the squeeze can linger into that phase, slightly delaying the artery from springing back open. When the heart is calm and beating slowly, this rarely matters. When the heart beats fast, during exertion, stress, or strong emotion, the relaxation phase shortens, and the lingering squeeze has proportionally more effect. This is why bridge symptoms, when they occur, are so often tied to exertion.

Why Most Bridges Cause No Trouble

The single most important thing to understand about muscle bridges is how common they are, and how rarely they cause problems. The numbers vary enormously depending on how you look for them, which is itself revealing.

Up to 1 in 4
people may have a myocardial bridge when hearts are examined closely, yet only a small fraction ever experience symptoms from it.
Imaging and autopsy studies, summarised in European Heart Journal, 2026

On a standard coronary angiogram, bridges turn up in only a few percent of people. On detailed imaging such as CT coronary angiography, the figure is much higher, and when hearts are examined directly the prevalence rises further still, into the range of one in five to one in four. The gap between these numbers tells the story: most bridges are shallow, short, and functionally silent. They are found incidentally, if they are found at all, and they sit quietly for a lifetime.

So if you have been told you have a bridge and you have no symptoms, the most likely situation by far is that the bridge is an anatomical footnote rather than a problem. It does not need fixing, and in most cases it does not need anything beyond the awareness that it is there.

When a Bridge Does Cause Symptoms

A minority of people with a bridge experience real symptoms, most commonly chest pain or tightness that comes on with exertion or stress and eases with rest. Some describe breathlessness, and some report that episodes last noticeably longer than a typical bout of exertional chest pain. Whether a particular bridge causes symptoms depends on several features working together.

Length of the bridge

A longer tunnelled segment means more of the artery is subject to the muscle’s squeeze with each beat. Longer bridges are more likely to be functionally significant than short ones.

Depth of the tunnel

How deeply the artery is buried in the muscle matters. A deeper bridge is compressed more forcefully, so deeper bridges tend to have a greater effect on blood flow than superficial ones.

Heart rate and exertion

A fast heart rate shortens the relaxation phase when the artery would normally recover. This is why bridge symptoms typically appear during exercise, stress, or strong emotion rather than at rest.

Coronary spasm

Bridges frequently sit alongside a tendency for the artery to spasm, or tighten suddenly. Spasm can drive symptoms independently of the bridge itself and changes how the condition is treated.

Endothelial function

The artery lining near a bridge is often under abnormal mechanical stress, which can impair its ability to relax and widen on demand. This contributes to symptoms in many bridge patients.

Plaque just upstream

The disturbed blood flow around a bridge tends to encourage fatty plaque to build up in the artery just before it, which can add its own contribution to symptoms and risk.

Because several of these factors often coexist, a bridge that looks modest on a picture can still be the source of meaningful symptoms, and a bridge that looks dramatic can sit silent. Anatomy alone does not settle the question. This is the central difficulty in managing bridges, and it shapes everything about how they are investigated.

Why a Bridge Is Harder to Diagnose Than It Sounds

It would be reasonable to assume that if a bridge shows up on an angiogram, the picture tells the whole story. In practice it rarely does. A standard coronary angiogram is good at finding flow-limiting blockages, but it has low sensitivity for bridges and tells you little about how deep a bridge is, how long it is, or whether it is actually responsible for a person’s symptoms.

When symptoms and anatomy do not obviously line up, cardiologists turn to more detailed assessment. Intravascular ultrasound, a tiny ultrasound probe threaded into the artery, is considered the most reliable way to confirm a bridge and measure its length and depth precisely. To judge whether the bridge is functionally significant, meaning it genuinely restricts flow under stress, specialised measurements are taken while the heart is pushed to work harder with a medication called dobutamine. Standard pressure-wire measurements used for ordinary blockages are not adequate for assessing a bridge, which is part of why bridge assessment is a specialised undertaking.

A particular pattern on a stress echocardiogram, a transient buckling in one part of the heart wall with the tip of the heart spared, can also raise suspicion of a bridge non-invasively. The broader point for patients is that confirming a bridge as the cause of symptoms is a deliberate, layered process, not a single glance at an angiogram.

Finding a bridge and proving that the bridge is the cause of someone’s pain are two very different things. Most bridges are bystanders. The clinical skill lies in identifying the minority that are genuinely to blame, and treating that group properly without over-treating everyone else.

Heart Matters editorial

How Symptomatic Bridges Are Treated

Medication comes first

For the large majority of people whose bridge does cause symptoms, medication is the first and usually the only treatment needed. The two mainstays are beta-blockers and calcium channel blockers. Both work in part by slowing the heart and easing the force of each contraction, which lengthens the relaxation phase and reduces the squeezing effect on the bridged artery. They can be very effective, and many people are managed comfortably on them for years.

One counter-intuitive point is worth knowing. Nitrates, which are a standard reliever for ordinary angina, are often used with caution in bridge patients and can sometimes make symptoms worse rather than better. If you have a bridge and find that a nitrate spray does not help your chest pain in the way you would expect, or seems to aggravate it, that is worth mentioning to your cardiologist rather than dismissing.

When an operation is considered

A small, carefully selected group of patients continue to have severe, life-limiting symptoms despite the best medication can offer, and have a bridge that has been confirmed as genuinely significant on detailed testing. For this group, a surgical option exists. The preferred operation is called surgical unroofing, in which the surgeon carefully divides the band of muscle lying over the tunnelled artery, freeing the vessel to return to the surface where it belongs.

Two other approaches, placing a stent inside the bridged segment or performing a coronary artery bypass, have generally proved less satisfactory for bridges specifically, which is why unroofing has become the favoured operation in suitable patients. It is important to stress that this is a treatment for a minority within a minority. The vast majority of people with a bridge will never come close to needing it.

What the Latest Research Shows

Until recently, a fair question about unroofing was whether its benefits lasted. Earlier work had shown good results at six months, but long-term evidence was thin. A 2026 study from Stanford University, published in the European Heart Journal, has now provided the most substantial answer to date.

The researchers followed 218 patients who had undergone surgical unroofing of a significant bridge in the left anterior descending artery after medication had failed to control severe angina. The patients were relatively young, with a median age of 49, and around 60% were women. They were followed for a median of five years.

Nearly 9 in 10
patients reported a meaningful, lasting improvement in their angina five years after surgical unroofing, with episodes typically falling from weekly to monthly.
Pargaonkar et al., European Heart Journal, 2026

Across every measure of symptoms and quality of life, patients reported significant and durable improvement, and most needed fewer anti-anginal medications afterwards than before. When the surgical patients were compared with a closely matched group who had a similarly significant bridge but were managed with medication alone, the surgical group showed greater relief from physical limitation and from the frequency of their angina. Importantly, the operation proved safe in experienced hands, with a low rate of major cardiac events over the follow-up period and none of those events attributed to the surgery itself.

The practical message for patients is measured rather than dramatic. For the specific, carefully selected group with a confirmed significant bridge and severe symptoms that medication cannot control, surgical unroofing is now backed by solid long-term evidence as a worthwhile option. It is not a treatment for an incidental finding, and it is not a first step. It is a well-supported last resort for those who genuinely need it.

The Bridge Is Rarely the Whole Story

One of the most useful insights from the recent research is that a bridge often travels with company. In the Stanford group, who were of course a highly selected population with difficult symptoms, almost all had a small build-up of fatty plaque in the artery just upstream of the bridge, and the great majority showed evidence of coronary spasm or of an artery lining that did not relax normally on testing.

This matters for two reasons. First, it explains why a few patients still have some symptoms even after a technically successful unroofing: if spasm or lining dysfunction was contributing, removing the muscle band does not address that part of the problem, and ongoing medication may still be needed. Second, the tendency for plaque to form just before a bridge is part of why attention to general cardiovascular risk, including the standard modifiable risk factors, remains relevant even when the headline issue is a structural one present from birth.

Heart Matters Resource

When in Doubt, Get Checked Out

If you have been told you have a muscle bridge and you are experiencing chest pain, breathlessness, or symptoms on exertion, those symptoms are worth a proper conversation with your cardiologist rather than assuming the bridge is harmless.

Read: When in Doubt, Get Checked Out →

Conclusion

A myocardial bridge is, for most people, exactly what it usually sounds like when a cardiologist mentions it in passing: a common quirk of heart anatomy that asks nothing of you and changes nothing about your life. If you have one and no symptoms, that is almost certainly where the story ends.

For the minority who do have symptoms, a bridge is a real and treatable condition. The key is careful assessment to confirm whether the bridge is genuinely the cause, sensible use of medication for the many, and a well-evidenced surgical option held in reserve for the few who need it. If you have a bridge and symptoms that affect your daily life, the right next step is not to worry alone but to have it properly evaluated, because the difference between a harmless bystander and a treatable problem is exactly the kind of question modern cardiology is now well equipped to answer.

White Coat Hypertension: When Your BP Spikes at the Doctor’s

May 29, 2026

Doctor measuring blood pressure of patient. white coat hypertension

Key Points

White coat hypertension is when your blood pressure reads high in the clinic but sits in the normal range during ordinary daily life. It is common, affecting up to one in three people whose office readings are raised.
It is caused by a stress response to the medical setting itself, not by a fault in your heart or blood vessels. The reading is real, but it does not reflect your usual blood pressure.
The only reliable way to confirm it is to measure blood pressure away from the clinic, using either a 24-hour ambulatory monitor or a structured week of home readings.
White coat hypertension is not always harmless. Some people go on to develop sustained high blood pressure, so ongoing monitoring matters even when no medication is started.
Its mirror image, masked hypertension, is the more dangerous pattern: normal in the clinic, high at home, and easy to miss without out-of-office measurement.

The cuff tightens, the nurse watches the dial, and the number that appears is higher than anything you ever see at home. It happens every visit. You feel perfectly well, your home readings are reassuring, and yet the clinic keeps telling you your blood pressure is up. If this sounds familiar, you may have white coat hypertension.

It is one of the most common and most misunderstood findings in everyday medicine. The reading on the machine is not wrong. Your blood pressure really did rise in that moment. The question is whether that rise reflects how your heart and arteries behave during the other 23 hours of the day, when no one is watching.

Getting that question right matters. Treat white coat hypertension as though it were sustained high blood pressure and a person can end up on medication they do not need. Dismiss it entirely and you can miss the early warning that genuine hypertension is developing. The path between those two errors runs through one simple idea: measure blood pressure where life actually happens.

What White Coat Hypertension Actually Is

White coat hypertension describes a specific pattern. Blood pressure measured in a clinic or surgery is in the hypertensive range, while blood pressure measured away from the clinic is normal. The term comes from the white coats traditionally worn by doctors, though the effect has far more to do with the setting than the clothing.

The mechanism is a stress response. Being assessed by a health professional, sitting in an unfamiliar room, anticipating bad news, or simply rushing to make the appointment can all trigger a brief surge in heart rate and blood pressure. This is the same fight-or-flight system that sharpens your senses before a job interview. In most people it settles within minutes of leaving. For some, it switches on reliably the moment a cuff appears.

This is different from anxiety as a diagnosis. Many people with white coat hypertension do not feel anxious at all. The body responds to the clinical context automatically, below the level of conscious worry, which is part of why telling someone to relax so rarely lowers the number.

If the two numbers in a blood pressure reading have always been a little mysterious, this short explainer walks through what systolic and diastolic actually mean.

Watch · Heart Matters

Systolic and diastolic, explained. A plain-English guide to what the two numbers in a blood pressure reading actually mean.

How Common Is It?

White coat hypertension is far from rare. Across large studies, when people with raised office readings are checked properly away from the clinic, a substantial proportion turn out to have normal everyday blood pressure.

15 to 30%
of people with high readings in the clinic are found to have white coat hypertension once their blood pressure is measured during normal daily life
International blood pressure registries

The effect tends to be more pronounced in older adults and in people who have been told for years that they have high blood pressure. It can even appear in people already taking blood pressure medication, where it can make treatment look as though it is failing when in fact the everyday numbers are well controlled.

Why It Is Easy to Get Wrong

The trouble with a clinic reading is that it captures a single, atypical moment. A few minutes in a medical room, often after sitting in a waiting area or hurrying through traffic, is not a fair sample of a whole day. Yet for decades this single snapshot was the basis for diagnosing high blood pressure.

When the diagnosis rests on office readings alone, two opposite mistakes become possible. The first is overdiagnosis: labelling someone hypertensive, and starting lifelong treatment, when their true blood pressure is fine. The second is the reverse problem, where genuinely high blood pressure outside the clinic goes undetected because the office reading happens to look acceptable.

Modern guidelines now treat measurement outside the clinic as essential rather than optional. The same principle underpins our advice on monitoring your blood pressure at home: the numbers that matter most are the ones gathered during ordinary life, not in a single moment of clinical stress.

White Coat Versus Masked Hypertension

White coat hypertension has a mirror image, and understanding both makes the whole picture clearer. They are opposite patterns, and they carry very different levels of risk.

White Coat Hypertension

High in the clinic, normal at home. Risk is generally lower than sustained high blood pressure, but it can progress over time, so it needs watching rather than ignoring.

Masked Hypertension

Normal in the clinic, high at home. This is the more concerning pattern, because the raised blood pressure quietly damages arteries and the heart while routine checks look reassuring.

Masked hypertension is the more dangerous of the two precisely because it hides. A person feels well, their clinic readings look fine, and no one suspects a problem, while their blood pressure runs high during work, sleep, and daily activity. This is part of why a single normal reading in the surgery is no longer considered enough to rule high blood pressure out.

How It Is Diagnosed

Confirming white coat hypertension means comparing clinic readings with readings taken during normal life. There are two reliable ways to do this, and your doctor may use either or both.

Ambulatory monitoring

A small device worn for 24 hours takes automatic readings during the day and overnight. It gives the fullest picture, including how blood pressure behaves during sleep.

Home monitoring

A validated upper-arm monitor used at set times over about a week. Readings taken morning and evening, while seated and rested, build a reliable everyday average.

The thresholds differ slightly between settings, which surprises many people. Clinic readings use one cut-off for diagnosing high blood pressure, while home and daytime ambulatory averages use a slightly lower one. This is normal and expected, because blood pressure is genuinely a little lower in relaxed, familiar surroundings.

For a closer look at why the clinic setting itself nudges your reading upward, this video explains what is happening in the body during that moment.

Watch · Heart Matters

The white coat effect, up close. Why the clinic setting itself can push your reading up, and what is happening in the body.

A blood pressure reading is a moment, not a verdict. The honest answer almost always comes from measuring it where the patient actually lives their life.

Prof. Peter Barlis, Interventional Cardiologist

Does It Need Treatment?

For true white coat hypertension, where everyday blood pressure is genuinely normal, medication is often unnecessary. The reading that rises only in the clinic does not, on its own, justify lifelong tablets. What it does justify is ongoing attention.

That is the key nuance. White coat hypertension sits somewhere between normal blood pressure and sustained high blood pressure in terms of long-term risk. A meaningful number of people with it will develop genuine hypertension within a few years. So the sensible approach is regular review, repeat out-of-office measurement, and attention to the everyday habits that keep blood pressure healthy.

Where lifestyle and risk factors are concerned, the same fundamentals apply as for anyone protecting their heart: maintaining a healthy weight, limiting salt and alcohol, staying physically active, and not smoking. Even something as accessible as regular walking contributes to keeping blood pressure in a healthy range over time.

When blood pressure is genuinely high outside the clinic, treatment follows the usual path. The medicines most often used include ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers, chosen to suit the individual. The decision to start, change, or hold any blood pressure medicine is one only your doctor or cardiologist can make for you, based on your full picture rather than a single number.

Getting an Accurate Reading at Home

If you are monitoring your own blood pressure, a few simple habits make the readings far more trustworthy. Small details in technique can shift a result by enough to change a diagnosis.

Sit and settle first

Rest quietly for five minutes before measuring. Sit with your back supported, feet flat on the floor, and legs uncrossed.

Support your arm

Rest your arm on a table so the cuff sits at heart height. An unsupported or dangling arm can push the reading up noticeably.

Measure twice, same times

Take two readings a minute apart, morning and evening, for several days. Record them all rather than picking the lowest.

Avoid caffeine, exercise, and smoking for at least 30 minutes beforehand, and empty your bladder first, as a full bladder can raise the reading. Use a validated upper-arm monitor rather than a wrist device, and bring your log to your next appointment so the pattern, not just a single number, guides the conversation.

Heart Matters Resource

When in Doubt, Get Checked Out

If your clinic and home readings keep telling you different stories, that is worth investigating properly rather than guessing. A short period of out-of-office monitoring can settle the question for good.

Read: When in Doubt, Get Checked Out →

Conclusion

White coat hypertension is a reminder that a blood pressure reading is a measurement of a moment, not a final judgement on your heart. The number that climbs in the clinic is genuine, but it tells only part of the story. The fuller answer comes from seeing how your blood pressure behaves across an ordinary day.

If your clinic readings have been high but you suspect they do not reflect your everyday self, the practical step is straightforward: ask about ambulatory or home monitoring, measure carefully, and review the pattern with your doctor. Whether the outcome is reassurance or the early detection of genuine high blood pressure, you come away knowing your real numbers, which is exactly where good heart care begins.

Stroke and TIA Explained

May 31, 2026May 17, 2026

Brain MRI scans showing imaging used after stroke and TIA assessment

Key Points

A stroke happens when blood flow to part of the brain is cut off and brain cells begin to die. A TIA, or transient ischaemic attack, causes the same symptoms, but the blockage clears on its own before permanent damage occurs.
A TIA is a medical emergency, not a minor event. The risk of a full stroke is highest in the 48 hours that follow, so rapid assessment and treatment in that window makes an enormous difference.
Investigations after a stroke or TIA focus on finding the cause: narrowing in the neck arteries, an irregular heart rhythm called atrial fibrillation, a structural problem with the heart, or abnormal blood clotting.
The right medications started promptly after a TIA, including blood thinners, blood pressure treatment, and statins, significantly reduce the risk of a subsequent stroke.
A TIA is not a frightening endpoint. It is an opportunity. The evidence that acting quickly and comprehensively prevents stroke is among the strongest in all of vascular medicine.

A stroke or TIA can feel frightening when the symptoms first appear. One side of the face droops. A hand will not grip. Words come out wrong. Whether those symptoms last two minutes or two hours, they mean something important is happening that demands to be taken seriously.

A TIA is one of the most important medical events a person can experience, not because of the symptoms themselves, which resolve completely, but because of what they represent. The brain’s blood supply was briefly interrupted. The fact that it recovered fully this time does not mean the underlying cause has gone away.

The good news, and this is the central message, is that medicine now has highly effective ways to respond. The window between a TIA and a potential stroke is narrow, but it is also a genuine opportunity to intervene. The people who do best are those who engage with that opportunity quickly and completely.

What Is a Stroke?

A stroke happens when blood flow to part of the brain is suddenly interrupted. There are two main types. An ischaemic stroke occurs when a clot blocks one of the arteries supplying the brain. A haemorrhagic stroke occurs when there is bleeding from a blood vessel in or around the brain. In both situations, the affected area of the brain is at risk of injury, which is why time is so important in treatment.

The effects depend on which part of the brain is affected. Speech, movement, vision, balance, and memory can all be disrupted. Some effects improve significantly over time with rehabilitation, while others can be longer lasting or permanent. This is precisely why preventing a first stroke, or a second one, matters so much.

What Is a TIA?

A TIA, or transient ischaemic attack, produces exactly the same symptoms as a stroke, but the blockage clears on its own before permanent damage occurs. Symptoms appear suddenly, typically peak within seconds to a minute, and then resolve completely. In most cases this happens within minutes, though by definition it occurs within 24 hours.

Brain imaging after a true TIA shows no area of permanent damage. This is what distinguishes it from a minor stroke, though the immediate management of both is identical.

It is sometimes called a “mini-stroke”, but that name does it a serious disservice. A TIA is not a small event. It is a clear warning that the blood supply to the brain is not right, and that the risk of a full stroke in the days and weeks ahead is significantly elevated.

I never dismiss a TIA because the symptoms have passed. The fact that the brain recovered is exactly what gives us the best possible chance to prevent what could come next.

Prof. Peter Barlis, Interventional Cardiologist

1 in 10
people who have a TIA will go on to have a full stroke within 3 months without treatment, with the highest risk concentrated in the first 48 hours.
American Stroke Association

Recognising the Signs: FAST

The FAST acronym captures the most important warning signs of stroke and TIA. Knowing it can save a life. TIA symptoms are neurological. They reflect whichever part of the brain has been briefly deprived of blood. They come on suddenly and without warning. The key word is sudden.

If you see any of these signs, call 000 immediately. Do not wait. Do not drive to hospital. Every minute matters.

F — Face. Sudden drooping or weakness on one side. Ask the person to smile. Is it uneven?
A — Arms. Sudden weakness or numbness in one arm. Can they raise both arms and hold them there?
S — Speech. Slurred, confused, or absent speech, even briefly.
T — Time. Call emergency services immediately. Do not wait to see if symptoms resolve.

Other warning signs include sudden loss of vision in one eye, double vision, severe unexplained dizziness, or sudden loss of coordination. Even if everything resolves on the way to hospital, urgent assessment is still essential. A TIA that has passed is still a TIA.

What Investigations Will I Have?

The purpose of investigation after a stroke or TIA is not simply to confirm what happened. It is to find out why, because the answer determines the treatment. Your medical team will want to move through this quickly, often within the first 24 to 48 hours.

Brain imaging: MRI and CT

The first priority is imaging the brain. A CT scan is often performed first in the emergency setting because it is fast and widely available, and can quickly exclude a bleed in the brain. An MRI scan follows when possible, as it is more sensitive. MRI can identify whether any permanent damage has occurred, and can also reveal older areas of reduced blood flow that may point to the underlying cause.

When the MRI shows multiple small areas of damage scattered across different parts of the brain, this is a strong signal that clots are being released from somewhere into the circulation, often from the heart. Finding that source becomes the priority.

Carotid artery ultrasound

The carotid arteries run up either side of the neck and supply blood directly to the brain. A build-up of fatty plaque in these arteries, called carotid stenosis or narrowing, is one of the most common and treatable causes of stroke and TIA.

A carotid Doppler ultrasound is a simple, painless scan that measures blood flow through these arteries. If significant narrowing is found on the side corresponding to your symptoms, a procedure to clear or widen the artery may be recommended, and the evidence for doing this promptly after a TIA is strong.

Heart rhythm monitoring: finding atrial fibrillation

Atrial fibrillation, or AF, is responsible for approximately one in five strokes. AF is an irregular heart rhythm in which the heart beats chaotically rather than in a coordinated fashion. When this happens, blood can pool in a small pouch in the left side of the heart called the left atrial appendage, forming a clot that can then travel to the brain.

The challenge is that AF often comes and goes rather than being present all the time. This means a standard ECG, which records the heart rhythm for only a few seconds, may look entirely normal even in someone who has AF. Longer-term monitoring is often needed to catch it.

Monitor Type	How Long It Records	What It Detects
Standard ECG	A few seconds	AF present at the exact moment of recording
Holter monitor	24 to 48 hours	AF that comes and goes over a day or two
Patch monitor	Up to 14 days	Infrequent AF that short monitoring misses
Implantable loop recorder	Up to 3 years	Very infrequent or hidden AF, highest sensitivity

When longer-term monitoring is needed

Sometimes a Holter or patch monitor comes back normal, but the clinical picture still strongly suggests the heart is the source of the problem. This is particularly the case when MRI has shown multiple small areas of damage in different parts of the brain, which points toward clots originating from a single source (often the heart) and being carried through the circulation.

In this situation, your specialist may recommend an implantable loop recorder. It is a small device, roughly the size of a USB stick, placed just beneath the skin of the chest under local anaesthetic in a minor procedure. It monitors the heart rhythm continuously for up to three years, transmitting data wirelessly to your cardiologist.

Studies have shown that prolonged monitoring with a loop recorder detects AF in a significant proportion of patients whose stroke initially had no clear cause. Finding AF months or even years after the original event still matters enormously, because it changes treatment from antiplatelet therapy to anticoagulation and substantially reduces the risk of a further stroke.

If your specialist has recommended a loop recorder, this reflects a thorough and proactive approach, not a sign that something has been missed.

Echocardiogram: imaging the heart

An echocardiogram is an ultrasound scan of the heart that shows its structure, function, and valves in detail. After a stroke or TIA, it helps identify whether the heart itself may be the source of a clot.

Conditions that can cause clots to form in the heart include reduced pumping function, valve disease, and a patent foramen ovale, or PFO. This is a small hole between the upper chambers of the heart that is present in around one in four people and that can allow clots to cross directly into the arterial circulation.

When a standard echocardiogram does not provide a clear enough view, a transoesophageal echocardiogram, or TOE, can be performed. A small probe is passed gently down the oesophagus, which sits directly behind the heart, giving a much closer and more detailed image of the heart and the large blood vessel that leaves it.

Blood tests

Blood tests assess cholesterol levels, including LDL, HDL, and triglycerides, along with blood glucose and HbA1c (a measure of your average blood sugar over the past three months) to screen for diabetes. A full blood count looks for conditions that increase the tendency to form clots, such as polycythaemia (an excess of red blood cells) or thrombophilia (an inherited tendency to form clots more readily than normal).

One marker worth asking about specifically is Lp(a), or lipoprotein(a). This is a lesser-known type of cholesterol-related particle that is not included in standard cholesterol tests. It is largely determined by genetics, and elevated levels independently raise the risk of both stroke and heart disease. As targeted therapies for elevated Lp(a) are now becoming available, identifying it early is increasingly meaningful. Read more in our article on lipoprotein(a) and inherited heart risk.

Medications That Reduce the Risk of a Future Stroke

The evidence base for stroke prevention after TIA is strong and well established. Several different classes of medication are used, and starting the right ones promptly is where much of the long-term risk reduction occurs.

The information below describes the main categories used in this setting and explains why each one matters. It is not a recommendation about your specific regimen. The choice of medication, combination, dose, and duration is an individual clinical decision that sits with your neurologist, cardiologist, and treating team.

Blood-thinning medications

Blood-thinning medications fall into two main groups, and they work in different ways. Antiplatelet medications, such as aspirin and clopidogrel, reduce the tendency of platelets (the tiny blood cells involved in clot formation) to stick together. Anticoagulants, such as warfarin and the newer direct oral anticoagulants (DOACs) including apixaban and rivaroxaban, work further along the clotting pathway and are more effective at preventing clots formed inside the heart.

Which group is used depends on the cause of the stroke or TIA. After a stroke or TIA not caused by atrial fibrillation, antiplatelet therapy is generally the cornerstone. In some situations, particularly the high-risk period immediately after a TIA, a second antiplatelet agent may be added for a defined period of time. Whether one or two agents are used, and for how long, is a careful clinical judgement made by your treating team based on the specific cause and your individual risk profile.

If atrial fibrillation is identified as the cause, the approach changes. Anticoagulants are generally more effective than antiplatelets in this setting because they target clots formed in the heart. Most patients with AF who would have once been treated with warfarin are now treated with a DOAC instead, since DOACs are generally easier to take, do not require regular blood tests for monitoring, and have a favourable safety profile. The choice of agent, the timing of starting it after the event, and the balance against any bleeding risk are decisions made by your specialist team.

Blood pressure treatment

High blood pressure is the single most important modifiable risk factor for stroke. Even modest, sustained reductions in blood pressure translate into meaningful reductions in the risk of a recurrent event.

ACE inhibitors are one class of blood pressure medication often used in this setting. The landmark PROGRESS trial showed a significant reduction in recurrent stroke with ACE inhibitor-based therapy after a first stroke or TIA, even in patients whose blood pressure was not markedly elevated. The benefit appeared to extend beyond simple blood pressure lowering. Several other classes of blood pressure medication are also effective, and the right combination for you depends on your other conditions and is a decision for your treating team.

Statins and cholesterol management

Statin therapy is often part of long-term care after a stroke or TIA, sometimes regardless of the baseline LDL cholesterol level. Statins do more than lower cholesterol. They stabilise arterial plaque, reduce inflammation in blood vessel walls, and lower the risk of future events through mechanisms that go beyond simple lipid reduction.

Lp(a) deserves specific mention here too. Standard lipid panels do not routinely include it, yet elevated Lp(a) is an independent risk factor for stroke and coronary artery disease. If your Lp(a) has not been checked, it is worth raising with your doctor, particularly as targeted therapies are becoming available.

Lifestyle Changes That Make a Meaningful Difference

Medications work best alongside genuine lifestyle change. The combination is more powerful than either alone.

Stop smoking

The single highest-impact change available, if relevant to you. Your doctor can help with cessation support and prescription options.

Move daily

Regular walking counts. Small and consistent beats occasional and intense, and 30 minutes most days is a realistic starting target.

Eat Mediterranean

A Mediterranean-style diet has the strongest evidence base for both heart and brain health. Olive oil, vegetables, legumes, oily fish, nuts.

Check your blood pressure

A home monitor is a small investment with a large payoff. Knowing your numbers makes the conversation with your doctor far more useful.

Stay engaged with your team

Long-term follow up matters. Knowing your medications, your targets, and what to ask at each appointment keeps you in control of the plan.

Protect your sleep

Poor sleep raises blood pressure and stress hormones. If snoring or daytime tiredness is significant, ask about obstructive sleep apnoea.

These do not all need to happen at once. Starting with the highest-impact change first, usually blood pressure control or smoking cessation if relevant, and building from there is both realistic and effective.

Heart Matters Resource

When in Doubt, Get Checked Out

If you or someone with you develops sudden facial drooping, arm weakness, speech difficulty, or any other sudden neurological symptom, even one that resolves quickly, call 000 immediately. Do not drive to hospital. Do not wait to see if things improve. A TIA that has passed is still a TIA, and the window for intervention is narrow.

Read: When in Doubt, Get Checked Out →

Questions to Discuss With Your Doctor

Knowing which questions to ask puts you in a much stronger position at every appointment. Here are the ones that matter most after a stroke or TIA:

What do you think caused my event, and what investigations are being arranged to find out?
Has my MRI shown any pattern that suggests clots from a cardiac source?
Do I need longer-term heart monitoring, and which type would you recommend?
Which medications am I starting, and what does each one do?
What are my blood pressure and LDL cholesterol targets?
Has my Lp(a) been checked, and if not, should it be?
What is the most important lifestyle change for me to prioritise first?

Conclusion

A stroke or TIA is serious, but it is also one of the most actionable events in medicine. The investigations that follow are not just about understanding what happened. They are about finding the specific, treatable causes that can be addressed.

The people who navigate this best are those who understand what happened, engage fully with the investigation process, and commit to the long-term prevention plan their team puts in place. That is not a passive role. It is an active one, and it makes a real and measurable difference.

Hypertrophic Cardiomyopathy: What HCM Actually Means

May 13, 2026

Most people with HCM live completely normal lives. Here is what the diagnosis means, what monitoring is needed, and why the outlook is better than most expect.

Stents or Bypass Surgery: How Your Heart Team Decides

May 31, 2026April 27, 2026

Key points

The choice between stents and bypass surgery depends on the complexity of your coronary disease, not just how blocked your arteries are
The SYNTAX trial, a landmark collaboration between cardiologists and cardiac surgeons, created the evidence base that guides this decision today
Your heart team uses several scoring tools to personalise the recommendation for you
In most cases there is time. This decision is made carefully, with your full understanding and agreement
No calculator replaces the Heart Team conversation. You are at the centre of this decision

I have spent more than fifty years in interventional cardiology. When I began my career, a blocked coronary artery was a life-altering diagnosis. The options were limited, the procedures crude by today’s standards, and the anxiety felt by patients and their families was, I suspect, not so different from what many of you reading this are feeling right now.

The field has changed beyond recognition. The early promise of pharmacotherapy: medications to slow the disease, relieve symptoms, reduce risk. The arrival of balloon angioplasty in the late 1970s, which felt revolutionary at the time: the idea that you could open a blocked artery from the inside, through a catheter no wider than a drinking straw, without a single incision on the chest. Then came the bare metal stent, a small metal scaffold that held the artery open after the balloon was deflated, which solved one problem and introduced another. Then drug-eluting stents, coated with medication to prevent the artery from narrowing again, and which changed everything.

Each of these advances was built on evidence: on clinical trials, on thousands of patients who gave their time, trusted their doctors, and allowed themselves to be part of something larger than their own treatment. If you have ever participated in a clinical trial, the advances that benefit cardiac patients today exist in part because of you. That debt is rarely acknowledged as clearly as it should be.

If you have just been told you need stents or bypass surgery

If you are reading this, you may have recently been told that you have significant coronary artery disease. Perhaps your angiogram has shown blockages in one or more of the arteries that supply blood to your heart. Perhaps your cardiologist has mentioned the words stents or bypass surgery, and perhaps, in that moment, the room felt a little smaller.

Coronary angiogram showing the heart arteries — A coronary angiogram

During an angiogram, a thin flexible catheter is passed into the coronary arteries and a small amount of contrast dye is injected. The dye makes the arteries visible under X-ray, allowing your cardiologist to see exactly where plaque has built up and where blood flow is restricted. This is the investigation that forms the foundation of your Heart Team’s decision.

That feeling is entirely understandable. It is one of the more confronting conversations medicine asks patients to have. But I want to offer you something before we go any further: reassurance.

The decision about how best to treat your coronary disease is not arbitrary. It is not a coin toss. It is the product of decades of rigorous clinical research, including a landmark trial that I had the privilege of leading, and it is made by a team of specialists whose entire professional lives have been devoted to getting this decision right for patients exactly like you.

What follows is an attempt to explain how that decision is made, what your heart team is weighing up, and what you deserve to understand about your own care.

The question that needed an answer

By the early 2000s, interventional cardiology was at a crossroads.

Drug-eluting stents had arrived and the results were remarkable. For the first time, we could place a stent in a blocked coronary artery and dramatically reduce the chance of it narrowing again, the problem called restenosis that had plagued balloon angioplasty and bare metal stents for two decades. Cardiologists were understandably excited. The technology was advancing rapidly, and we were beginning to treat increasingly complex disease, multiple blocked arteries, blockages in critical locations, patterns of disease that had previously belonged almost exclusively to the cardiac surgeons.

But excitement is not evidence.

The honest truth was that we were pushing into territory where the data had not yet followed. Bypass surgery had decades of long-term outcome data behind it. It was proven, reproducible, and for patients with complex multivessel coronary disease, it had saved an enormous number of lives. The question that cardiologists and cardiac surgeons both knew needed answering was whether stents could match those outcomes in the most complex cases, or whether surgery remained the stronger choice.

What made this moment unusual in medicine was what happened next. Rather than cardiologists and surgeons arguing their respective corners, the two disciplines sat down together and agreed to find out.

A collaboration built on honest questions

The SYNTAX trial was conceived as a genuine partnership. On the cardiology side, I led the study design and execution. On the surgical side, Professor Friedrich Mohr of Leipzig brought the same rigour and the same commitment to finding the right answer, regardless of what that answer turned out to be.

We recruited 85 centres across Europe and the United States and enrolled 1,800 patients with either three-vessel coronary disease, significant blockages in all three of the main arteries supplying the heart, or left main disease, where the blockage sits at the origin of the coronary tree and carries particular weight in terms of risk. Every patient was assessed by both a cardiologist and a cardiac surgeon before randomisation. The Heart Team concept, the idea that complex coronary disease should never be decided by one specialty alone, was not an afterthought. It was built into the trial’s DNA from the very first protocol meeting.

Patients were randomised to receive either percutaneous coronary intervention with drug-eluting stents, the technical term for catheter-based stenting procedures, commonly abbreviated to PCI, or coronary artery bypass grafting, the surgical procedure commonly known as bypass surgery or CABG. We followed them for one year initially, then five years, then ten.

What the trial found, and why it mattered

The results, when they came, were nuanced in the way that the best science always is. They did not declare a single winner. They did something more valuable: they identified who benefited most from each approach.

Patients with less complex coronary disease did equally well with stents as with surgery at five and ten years. But patients with more complex disease, multiple blockages, difficult anatomy, involvement of critical vessel segments, did better with bypass surgery at five and ten years. The difference was meaningful, and it was consistent across multiple analyses.

The critical insight was this: it was not simply a question of stents versus surgery. It was a question of which patient, with which anatomy, benefits most from which treatment. And to answer that question properly, we needed a way to measure coronary complexity objectively. That tool became the SYNTAX score.

Research Spotlight

10 Years of SYNTAX: What a Decade of Research Taught Us About Your Heart

Most medical studies follow patients for a year or two. The SYNTAX trial followed 1,800 patients for a full decade, one of the longest and most detailed studies ever conducted in heart disease treatment.

What did ten years of follow-up reveal? That the decision between stents and bypass surgery is not just about your arteries, it is about you as a whole person. Factors including whether you have diabetes, how well your heart pumps, your kidney function, your body weight, and even your mental health before the procedure were all found to influence long-term outcomes. Patients who were on good medical therapy, cholesterol medication, blood pressure treatment, consistently did better regardless of which procedure they had.

The ten-year data also confirmed that for patients with blockages in all three main heart arteries, bypass surgery provided a meaningful survival advantage over stenting. For patients with disease at the critical left main junction, outcomes were more comparable, and the decision depends heavily on the individual.

Serruys PW et al. 10 Years of SYNTAX: Closing an Era of Clinical Research After Identifying New Outcome Determinants. JACC: Asia, 2023.

The SYNTAX score: measuring the complexity of your coronary disease

Not all coronary disease is equal. A single, straightforward blockage in one artery is a fundamentally different clinical problem from three heavily calcified blockages across multiple vessels, one of which sits at a critical branching point where two arteries divide. The SYNTAX score gave the field a standardised, reproducible way to measure coronary complexity from the angiogram, the X-ray map of your coronary arteries, and express it as a single number.

Each significant blockage is assessed for its location, severity, length, and features that make it more or less technically challenging to treat. The individual scores are added together to produce a total SYNTAX score. The higher the number, the more complex the coronary anatomy.

Score band	What it means	General direction
Low, 22 or below	Fewer blockages, simpler anatomy	Stenting outcomes comparable to bypass surgery
Intermediate, 23 to 32	Moderate complexity, careful assessment needed	Heart Team decision: both options weighed carefully
High, 33 or above	Multiple blockages, complex anatomy	Bypass surgery generally favoured for long-term outcomes

Beyond the anatomy: the SYNTAX Score II

The SYNTAX Score II adds eight clinical variables, including age, kidney function, diabetes status, and lung function, to the anatomical score, producing two side-by-side estimates: predicted four-year mortality with PCI, and with CABG. It is a considerably more personalised tool, and increasingly the one your team will use when the decision is genuinely difficult. More recently it was updated using ten years of follow-up data from the full SYNTAX programme, producing more accurate long-term predictions.

What your heart team is actually looking at

The SYNTAX score captures the complexity of your coronary anatomy, but it is only one part of the picture. Before your heart team makes a recommendation, they are weighing up two distinct sets of information: what your arteries look like, and what you are like as a patient. Both matter enormously.

The patient

Age and frailty

Bypass surgery is a major operation. Frailty and other conditions influence whether its benefits outweigh its risks for you specifically.

Diabetes

Strong evidence favours bypass in diabetic patients with multivessel disease. The FREEDOM trial established this clearly.

Heart muscle function

The ejection fraction, how well your heart pumps, affects both the risk and likely benefit of each treatment option.

Kidney function

Kidney health is an important input into surgical risk scores and affects contrast dye management during procedures.

Prior heart surgery

A second operation on the chest carries significantly higher risk. Previous bypass often shifts the balance toward stenting.

Your preferences

Recovery time, lifestyle, and personal values matter. Where evidence supports either option, your informed preference shapes the decision.

Age and overall health. A fit 55-year-old and a frail 78-year-old with the same coronary anatomy may receive very different recommendations, and rightly so. For a patient with significant frailty, poor lung function, or multiple other medical conditions, the risks of surgery itself may outweigh its benefits, even when the anatomy would otherwise favour it.

Diabetes. Diabetes deserves special mention because the evidence here is particularly strong. The FREEDOM trial, a landmark study examining diabetic patients with multivessel coronary disease, found that bypass surgery produced meaningfully better long-term outcomes than stenting in this group. Diabetes accelerates disease progression throughout the coronary tree, and bypass surgery offers a degree of future-proofing that stents in individual lesions cannot replicate.

26%
relative reduction in major cardiovascular events with bypass surgery vs stenting at 5 years, in diabetic patients with multivessel coronary disease
Source: FREEDOM Trial, Farkouh ME et al, New England Journal of Medicine, 2012

Heart muscle function. How well your heart is pumping, measured as the ejection fraction, influences both the risk of any procedure and the likely benefit. The ten-year SYNTAX data showed that patients with reduced heart pumping function had significantly higher rates of adverse outcomes regardless of treatment, underlining the importance of protecting heart function from the outset.

Kidney function. Contrast dye used during angiography and stenting can stress the kidneys, and kidney function is an important input into surgical risk scores.

Previous heart surgery. A second operation on the chest carries significantly higher technical risk. In this situation, stenting, even for complex disease, may be the preferred option.

What you want. A patient who understands their options and has strong preferences about recovery time, lifestyle, or risk tolerance deserves to have those preferences heard and incorporated into the decision. This is not a minor consideration.

The lesions: your blockages

Number of vessels involved. Single-vessel disease is almost always treated with stenting when intervention is needed. Three-vessel disease is where the stents-versus-bypass discussion most often begins.

The left main coronary artery. This short but critical vessel supplies the majority of the heart muscle in most people. A significant blockage here carries particular weight and is always discussed by the full Heart Team.

Bifurcation lesions. Blockages at branching points are technically demanding to treat with stents and carry additional weight in the SYNTAX score.

Chronic total occlusions. An artery completely blocked for three months or more. CTOs can be opened with specialised stenting techniques by experienced operators, but they represent some of the most technically demanding work in interventional cardiology.

Calcification. Heavily calcified arteries resist the expansion needed to deploy a stent optimally. Specialised techniques, including rotational atherectomy, which uses a tiny high-speed burr to modify the calcium before stenting, have improved outcomes considerably.

Diffuse versus focal disease. Long segments of disease spread throughout a vessel are harder to treat completely with stents, and incomplete treatment is associated with worse outcomes than complete revascularisation.

What might push your team towards one option or the other

Your heart team will use scoring tools and imaging to guide their recommendation, but what most patients really want to know is: given my situation, which way does this tend to go? The table below sets out the circumstances that most commonly influence that decision, in plain terms. No single factor is decisive on its own; your team is weighing all of them together.

May favour bypass surgery

May favour stenting

Multiple blocked arteries with complex disease

Blockages in all three main coronary arteries, particularly with diffuse or complicated anatomy, can often be addressed more completely in a single bypass operation than through multiple stenting procedures.

Simpler or single-vessel disease

Where blockages are limited to one or two vessels, or the anatomy is straightforward, stenting achieves equivalent outcomes with far less recovery time. Surgery adds risk without adding benefit.

Diabetes

Diabetes tends to cause disease that is more widespread and progresses faster. Bypass surgery has shown consistently better long-term outcomes in this group, partly because it protects against future disease in vessels that appear normal today.

Chronic kidney disease

Significant kidney impairment increases the risk of complications from major surgery and general anaesthesia. When kidney disease is advanced, your team may judge that the risks of bypass outweigh its benefits, and stenting becomes the safer path.

Bleeding risk or inability to take blood thinners

Stenting requires two blood-thinning medications taken together for a period afterwards. If you have a significant bleeding history, need another operation soon, or cannot safely take these medicines, bypass surgery avoids this requirement entirely.

Significant lung disease or anaesthetic risk

Bypass requires a general anaesthetic and open-chest surgery. For patients with significant COPD, severe asthma, or other conditions affecting lung function, the anaesthetic risk alone may make bypass unsuitable. Stenting is performed under local anaesthetic and light sedation.

Good overall health and fitness for surgery

For a fit patient with complex multivessel disease, good heart and lung function, and no prior chest surgery, bypass offers highly durable revascularisation. The internal mammary artery graft has a patency rate exceeding 90% at ten years.

Advanced age or frailty

For older or frailer patients, the six to twelve week recovery from bypass, and the risks of major surgery, may outweigh the long-term advantage. A shorter procedure with a faster return to normal life is often the more appropriate choice.

Vessels suitable for graft attachment

Bypass works by attaching a graft vessel beyond the blockage. Where the artery beyond the blockage is of good calibre and accessible, grafts can be placed reliably and durably.

Disease in distal segments unsuitable for grafting

When disease affects the very end portions of coronary vessels, there may be no suitable landing point for a bypass graft. In this situation, stenting of accessible segments may be the only viable interventional option, even when the overall disease is complex.

Valve surgery also needed

If you need both coronary revascularisation and valve repair or replacement, bypass surgery and valve surgery can be performed together in a single operation. This avoids two separate procedures and is generally preferred when the surgical risk is acceptable. Your cardiac surgeon and cardiologist will weigh this carefully together.

High surgical risk with valve disease

Where surgery is considered too high risk, percutaneous options may be considered for both the coronary disease and the valve problem. For example, a patient with significant aortic valve disease and coronary artery disease who cannot safely undergo open-heart surgery may be considered for TAVI (transcatheter aortic valve implantation) alongside PCI. These decisions require particularly careful Heart Team discussion.

Good overall health and fitness for surgery

Previous open-heart surgery

A second operation on the chest carries significantly higher risk than a first. If you have had bypass surgery before, your team will almost always favour stenting for any subsequent coronary intervention, regardless of anatomy.

Remember

None of these factors is decisive on its own. Your heart team is weighing all of them together, alongside the precise detail of your coronary anatomy, to arrive at the recommendation that is right for you. If you are unsure why a particular approach has been recommended, ask. Understanding the reasoning will help you feel confident in the decision.

The scoring tools your heart team uses

No single score makes the decision. Together, the tools below help your team answer two distinct questions: how complex is this coronary disease to treat, and how much risk does this particular patient carry?

Tool	What it measures	Used by	Output
SYNTAX score	Coronary anatomy complexity: blockage location, severity, and technical difficulty	Cardiologist and surgeon together	Number: low, intermediate, or high complexity
SYNTAX Score II 2020	Anatomy plus clinical profile: age, kidney function, diabetes, lung disease, and more. Updated using 10-year follow-up data.	Heart Team for complex cases	Predicted outcomes with PCI vs CABG, side by side
EuroSCORE II	Surgical risk: patient factors influencing the risk of the operation itself	Cardiac surgeon	Estimated % risk of adverse outcomes from the surgical procedure
STS score	Surgical risk, complications, and likely hospital stay	Cardiac surgeon	Risk estimates for major complications and prolonged stay

A word of caution, and of reassurance

If you have been reading this section and finding yourself reaching for a calculator, I understand the impulse. Some of these scoring tools are accessible online, and I have no doubt that some of you will find them. My advice, as someone who spent decades helping to build these tools, is this: please use them as a conversation starter with your cardiologist, not as a verdict.

A SYNTAX score is calculated from a detailed analysis of your coronary angiogram by a trained clinician. The inputs are precise, technical, and require direct interpretation of imaging that takes years of experience to read accurately. More importantly, the score is only ever one input into a much larger conversation.

“No calculator has ever treated a patient. The decision about your coronary disease belongs to you and your team, together.”

Prof. Patrick W. Serruys

There is time

One of the things I most want patients to understand is that in the vast majority of cases, there is time. A patient with a heart attack in progress may require immediate intervention, but most patients facing the stents-versus-bypass conversation are not in that situation. They have had their angiogram. Their disease has been documented. They are stable.

Your case will typically be discussed at a formal Heart Team meeting, a structured review where your cardiologist and cardiac surgeon examine your imaging and scoring together and reach a consensus recommendation. You will then meet with each of them in turn. That process unfolds over days, sometimes a couple of weeks. It is not rushed.

The Heart Team model was built into the SYNTAX trial protocol from the very first meeting. It has since become a cornerstone of international cardiology guidelines. It exists for you.

When bypass surgery is the stronger choice

Bypass surgery, formally known as coronary artery bypass grafting (CABG), involves a cardiac surgeon creating new routes for blood to flow around blocked sections of your coronary arteries, using blood vessels harvested from elsewhere in your body, most often the internal mammary artery from inside your chest wall or the saphenous vein from your leg. It is open-heart surgery, requiring a general anaesthetic and a period on a cardiopulmonary bypass machine. Recovery takes weeks, not days. For the right patient, with the right anatomy, it remains one of the most effective and durable interventions in all of medicine.

Three-vessel disease with high SYNTAX score. The SYNTAX trial’s most consistent finding, confirmed at ten years of follow-up, was that patients with three-vessel disease and a high SYNTAX score had meaningfully better outcomes with bypass surgery, driven primarily by lower rates of repeat procedures and heart attack.

Diabetes with multivessel disease. The FREEDOM trial established clearly that diabetic patients with multivessel coronary disease do better with bypass surgery than stenting over the long term. The mechanism relates to the biology of diabetic coronary disease, diffuse, aggressive, and progressive, and the ability of bypass surgery to protect against future events.

Significant left main disease with additional complexity. For patients with left main disease combined with additional complex coronary disease, bypass surgery has consistently shown favourable long-term outcomes in the major trials.

When the patient is a good surgical candidate. A relatively young, fit patient with good heart and lung function, no prior sternotomy, and high-complexity three-vessel disease: this is the patient for whom bypass surgery was designed.

When prolonged dual antiplatelet therapy is a concern. Stenting requires dual antiplatelet therapy (DAPT), typically aspirin combined with a second agent such as clopidogrel or ticagrelor, for a period after the procedure to prevent clot formation within the stent. For patients who cannot tolerate prolonged DAPT due to bleeding risk, a planned surgical procedure, or other medical reasons, bypass surgery avoids this requirement entirely. The internal mammary artery graft does not carry the same clotting risk as a freshly deployed stent, making CABG a more appropriate choice in these situations.

When stenting is the right answer

Percutaneous coronary intervention (PCI, or stenting) involves a cardiologist passing a thin, flexible catheter through an artery in the wrist or groin, navigating it to the blocked coronary artery under X-ray guidance, and deploying a small metal scaffold, the stent, to open the artery and hold it open. Modern drug-eluting stents release a medication that prevents the artery from narrowing again. For the right patient, stenting offers something bypass surgery cannot: a same-day or next-day procedure, performed under local anaesthetic and light sedation, with most patients home within 24 to 48 hours.

	Stenting (PCI)	Bypass surgery (CABG)
How it works	Catheter through wrist or groin; stent opens blockage from inside	New routes around blockages using vessels from chest wall or leg
Anaesthetic	Local anaesthetic and light sedation	General anaesthetic
Hospital stay	24-48 hours for most patients	5-7 days typically
Recovery	Days to 1-2 weeks to normal activity	6-12 weeks for full recovery
Best suited to	Low to intermediate complexity; single or double vessel disease; high surgical risk	High complexity; three-vessel disease; diabetes with multivessel disease; left main with complexity
Long-term durability	Excellent in suitable anatomy; repeat procedures more common in complex disease	Internal mammary artery graft patency exceeds 90% at 10 years
Repeat procedure risk	Higher in complex multivessel disease	Lower long-term repeat intervention rate in suitable patients
Antiplatelet therapy (DAPT)	Required for a period post-procedure; bleeding risk and compliance must be considered	No prolonged DAPT requirement; advantage in patients with bleeding concerns or planned surgery

Low to intermediate SYNTAX score. The clearest indication for stenting over surgery is relatively straightforward coronary anatomy where the disease can be treated completely and safely. In this setting, the SYNTAX trial showed outcomes comparable to bypass at five and ten years.

Single and double vessel disease. For patients with significant disease in one or two coronary arteries, stenting is almost universally the preferred approach when intervention is needed.

High surgical risk. Where the EuroSCORE II indicates surgical risk outweighs the anatomical benefit of bypass, stenting, even of complex disease, may be the right answer.

When DAPT can be safely maintained. Stenting requires a period of dual antiplatelet therapy after the procedure. Where a patient can reliably tolerate this without bleeding concerns or planned surgery, this is not a barrier. For patients where DAPT compliance is straightforward, stenting remains an excellent option in appropriate anatomy.

Left main disease in lower complexity settings. The EXCEL and NOBLE trials concluded that stenting is a reasonable option for left main disease when the overall SYNTAX score is low to intermediate and the anatomy is suitable for complete revascularisation with stents.

The technology has moved on. The stents available today are not the stents of the SYNTAX trial era. Current-generation ultrathin drug-eluting stents, deployed by experienced operators, produce results that were simply not achievable when the original trial was designed. The evidence base continues to evolve, and the decisions your heart team makes for you are grounded in the best of what we know today.

Conclusion

The science exists to serve the patient in front of you. Not the patient in a trial, not the average across a population, but the person in the room, with their particular anatomy, their history, and their hopes about what comes next. No score has ever accounted for that. Your Heart Team has.

To the question patients most often ask me, which is better, stents or bypass, the honest answer is: it depends, and that is not an evasion. For straightforward disease, stenting is an excellent treatment with outstanding outcomes and a far shorter recovery. For complex, multivessel disease, particularly with diabetes or a high SYNTAX score, bypass surgery has proven itself over decades of follow-up data. Both treatments, done well in the right patient, extend life and relieve symptoms. The goal of everything described in this article is to help your team identify which of those patients you are.

Ask questions. Ask your cardiologist to explain your SYNTAX score and what it means for you specifically. Ask the cardiac surgeon what recovery would look like. An informed patient is always a better partner in their own care.

Patrick W. Serruys

Questions to ask your heart team:

What is my SYNTAX score, and what does it mean for my specific situation?
Has my case been discussed at a Heart Team meeting with a cardiac surgeon?
Which treatment does the team recommend, and why?
What are the risks of each option for me specifically, not in general, but for my anatomy and my health?
If I choose stenting, will intracoronary imaging be used to guide the procedure?
What happens if I need a repeat procedure in the future?
How long do I have to make this decision, and who can I speak to if I have more questions?

There are no unreasonable questions when it comes to your heart. Your team expects them and welcomes them.

Prof. Patrick Serruys with Prof. Peter Barlis at Sydney Valves 2026

“During a recent visit to Australia for Sydney Valves 2026, I had the pleasure of reconnecting with Prof. Peter Barlis, my former PhD student and a longstanding collaborator. Peter has built something genuinely unique in Heart Matters, a patient education resource grounded in real clinical expertise, written by the people who actually treat these conditions. In a field where patients are often left to navigate complex decisions with little support, it fills an important gap. I was glad to contribute to it.”

Prof. Patrick W. Serruys

Photographed with Prof. Peter Barlis, Founding Editor of Heart Matters, Sydney Valves 2026

Key trials and research referenced in this article

SYNTAX trial: Serruys PW et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine, 2009
SYNTAXES, 10-year follow-up: Thuijs D, Serruys PW et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up. The Lancet, 2019
10 Years of SYNTAX, state of the art review: Serruys PW et al. Closing an Era of Clinical Research After Identifying New Outcome Determinants. JACC: Asia, 2023
FREEDOM trial: Farkouh ME et al. Strategies for multivessel revascularization in patients with diabetes. New England Journal of Medicine, 2012
EXCEL trial: Stone GW et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. New England Journal of Medicine, 2016
NOBLE trial: Makikallio T et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis. The Lancet, 2016

This article is intended for patient education only and does not constitute individual medical advice. Please discuss your specific circumstances with your treating cardiologist.

Single, Double, Triple, Quadruple Bypass: What Does the Number Mean?

May 31, 2026April 24, 2026

Key points

The number of bypasses — single, double, triple, quadruple — describes how many coronary arteries were rerouted, not how serious or dangerous the operation is.
A triple bypass on a fit, healthy patient is often a more straightforward operation than a single bypass on someone with poor heart function or multiple other medical conditions.
The goal of bypass surgery is to restore blood flow to every area of the heart that needs it. More bypasses often reflects a more thorough job, not a worse one.
The choice of vessel used for the bypass matters enormously for how long it lasts. The internal mammary artery is the gold standard — more than 9 out of 10 are still working well after 10 years. The radial artery comes a close second.
Recovery depends far more on your age, fitness, and heart function than on the number of bypasses performed. Modern recovery practices help patients get home and back to normal life faster.

In more than three decades as a cardiac surgeon, there is one moment in the pre-operative consultation that I have come to recognise instantly. I tell a patient they need a triple bypass, and I watch the calculation begin behind their eyes.

Triple must mean three times worse than single. It must mean three separate problems, three separate operations, or simply that their heart disease is three times as serious as it might have been. It must mean a longer recovery, a bigger risk, a harder road.

Patients also often ask where the “veins” are taken from, presuming that veins are the material mostly used to bypass blocked coronary arteries. Two other common questions are “are you cracking open my chest?” and “it must be very painful”.

None of these assumptions are correct. Clearing them up — calmly, carefully, and completely — is one of the most important conversations I have with patients before we go to theatre.

Your coronary arteries — a brief map

To understand what the number of bypasses means, you first need a basic picture of the arteries we are talking about.

Diagram of the heart showing the three main coronary arteries — LAD, LCx, and RCA — as seen in anterior view — **Figure 1.** The three main coronary arteries supplying the heart muscle, shown in anterior view as the surgeon sees them. The patient’s right side is on the viewer’s left.

The heart has three main coronary arteries — the blood vessels that wrap around its surface and supply the heart muscle with the oxygen and nutrients it needs to keep beating. When one or more of these arteries becomes significantly narrowed or blocked, the heart muscle downstream is deprived of blood flow. That is coronary artery disease, and bypass surgery is one of the ways we restore that flow.

The three arteries are the left anterior descending artery, known as the LAD, which runs down the front of the heart and supplies a large portion of the left ventricle (the heart’s main pumping chamber). The left circumflex artery, or LCx, which curves around the left side of the heart, supplying the back and left side of the left ventricle. And the right coronary artery, or RCA, which supplies the right side of the heart and, in most people, the bottom wall of the left ventricle.

The LAD is the most important of the three. Because it supplies such a large portion of the left ventricle, significant blockages here demand prompt attention, and it is almost always the most important artery that we bypass.

Each of these three main arteries also has significant branches that supply their own territories of heart muscle. The diagonal branches come off the LAD and supply the front and side wall of the left ventricle. The marginal branches come off the LCx and supply the side wall. When one of these branches is large and significantly diseased, it can benefit from its own bypass — and this is often where a fourth graft comes from.

What the number actually means

A single bypass means one artery has been bypassed. A double bypass means two. A triple bypass — the most common type — means three arteries have been bypassed, typically the three main coronary arteries. A quadruple bypass means four grafts have been placed, usually because one of the main arteries also has a large branch that is diseased and needs its own bypass.

That is it. The number describes how many new routes we created around blocked segments — nothing more, nothing less.

Figure 2

A traditional bypass arrangement

A bypass arrangement using the right internal mammary artery (RIMA), taken from inside the chest wall and crossed over to reach a coronary artery on the front of the heart, together with a saphenous vein graft from the leg.

Illustration: E. Jeannes

The number does not tell you how blocked the arteries were. It does not tell you how long the operation took. It does not tell you how serious your heart disease is compared to someone with a different number. And it certainly does not predict your recovery in any simple way.

The number of bypasses is best understood as a description of thoroughness. A surgeon who performs three bypasses on a patient with disease in all three main arteries has done a complete job. A surgeon who performs only one bypass on the same patient has left significant disease untreated — and that carries its own consequences.

The most common scenario

Triple bypass surgery is the most frequently performed type, because most patients who reach the point of needing surgery have significant disease in more than one artery. By the time coronary artery disease is severe enough to warrant surgery rather than stenting, it has often progressed throughout the coronary tree, affecting multiple vessels rather than a single isolated blockage.

This is not bad news. It is simply the nature of the disease, and it is exactly the scenario bypass surgery was designed to address.

Does more bypasses mean a more serious operation?

This is the question I am asked most often, and the honest answer is: not in the way most patients assume.

The duration and complexity of bypass surgery depends far more on the patient’s overall condition than on the number of grafts being placed. A triple bypass on a fit 58-year-old with good heart function, no diabetes, good lung function, and no prior cardiac surgery is a very different operation from a single bypass on a frail 75-year-old with a significantly weakened heart, impaired kidneys, and poor lung reserve. The first patient may be in theatre for three to four hours and home within five days. The second may face a considerably more complex course regardless of how many vessels were grafted.

What the surgical team is assessing before your operation is not primarily the number of bypasses required, it is you. Your age, your fitness, your heart muscle function, your other medical conditions, and whether you have had heart surgery before. These are the variables that shape the surgical risk, not the number written on the consent form.

3–5 hrs Typical theatre time for bypass surgery — whether single, double, or triple bypass in a suitable patient The additional time for each extra graft is generally 20–40 minutes

The grafts — what we use and why

Bypass surgery works by using a healthy blood vessel from elsewhere in the body to create a new route around the blocked section of a coronary artery. The vessel we choose — the graft — matters enormously for how long the bypass lasts.

The internal mammary artery — the gold standard

The left internal mammary artery (also called the left internal thoracic artery, or LIMA) runs along the inside of the chest wall and is the graft of choice for bypassing the LAD. The evidence for its longevity is extraordinary: more than 9 out of 10 of these grafts are still working well after 10 years, and many remain open at 20 years and beyond.

The reason is biological. The mammary artery is a living conduit. It adapts to its new role, responds to the demands of the coronary circulation, and resists the process of re-narrowing that affects vein grafts over time. When we place a LIMA-to-LAD graft, we are not simply creating a bypass — we are creating a durable, long-term solution for the most important artery in the heart.

Illustration of maximum arterial revascularisation, combining both mammary arteries with a radial artery graft

Figure 3

All arterial grafts

Both mammary arteries combined with a radial artery graft from the forearm. All three coronary territories bypassed using arterial grafts, offering the most durable long-term result in younger patients.

Illustration: E. Jeannes

Where two mammary arteries are used — a technique known as bilateral internal mammary artery grafting — the evidence suggests even better long-term outcomes, particularly in younger patients. This is a more demanding approach and is not suitable for everyone, but in the right patient it represents the highest standard of surgical revascularisation.

The radial artery

The radial artery — the artery at the wrist used to take your pulse — can also be harvested and used as a graft in selected patients. Its long-term success rates fall between the mammary artery and the saphenous vein, and it is particularly useful in younger patients where durability is the priority.

The use of this artery was pioneered here in Melbourne by my mentor, Prof Buxton, in the late 1990s. Harvested from the forearm, it allows for a quick recovery and good outcomes. This graft has now been shown to have very good early and long-term results, staying open for over 15 years.

Illustration of bilateral internal mammary artery grafting, with both left and right mammary arteries used as bypass grafts

Figure 4

Using both mammary arteries

Both the left and right internal mammary arteries used as arterial grafts. Evidence suggests even better long-term outcomes in suitable patients, particularly younger ones. This approach is technically demanding and is not suitable for everyone.

Illustration: E. Jeannes

It is worth remembering that arterial grafts are much better than the alternative — saphenous vein grafts, which start to block off at around five years.

Saphenous vein grafts

The saphenous vein — the long vein running along the inside of the leg — is the most commonly used graft after the mammary artery. It is harvested through a small incision or, increasingly, through minimally invasive techniques, and used to bypass the remaining vessels.

Vein grafts are reliable and effective, but they do not last as long as arterial grafts. About half of saphenous vein grafts are still fully open after 10 years, compared to more than 9 out of 10 for the LIMA. This is not a failure of the surgery; it is simply the biology of vein grafts placed into the high-pressure arterial circulation. It means that for younger patients, or those with a long life expectancy, using as many arterial grafts as possible is an important part of surgical planning.

Graft	Source	Still open at 10 years	Best used for
Left internal mammary artery (LIMA)	Inside chest wall	More than 9 in 10	LAD bypass — gold standard in almost all patients
Right internal mammary artery (RIMA)	Inside chest wall	More than 8 in 10	Second arterial graft — particularly in younger patients
Radial artery	Forearm	About 8 in 10	Additional arterial graft in suitable patients
Saphenous vein	Leg	About 5 in 10	Additional vessels — reliable and widely used

Quadruple bypass — and beyond

A quadruple bypass is less common than a triple, but far from rare. The fourth bypass almost always goes to one of the important branches of the three main arteries — most often a large diagonal branch off the LAD, or a significant marginal branch off the LCx — when that branch is diseased enough to be affecting heart muscle on its own.

So when your surgical team recommends a quadruple bypass, it does not usually mean you have a fourth main coronary artery that most people do not have. It means that one of the branches coming off your main arteries is large and important enough to warrant its own graft alongside the three main ones.

Quintuple bypass — five grafts — does occur, though it is uncommon. It typically involves the three main arteries plus two of their most significant branches, and is generally reserved for patients with very extensive coronary disease who are good surgical candidates.

I want to be clear about something important: the fact that a patient needs four grafts rather than three does not mean their operation is dramatically more dangerous or their recovery dramatically longer. It means their coronary disease was extensive enough to require four new routes, and that their surgical team was thorough enough to provide them.

Why a thorough job matters

One of the principles that guides every bypass operation I perform is the goal of restoring blood flow to every area of the heart that is at risk from significant disease. Surgeons call this complete revascularisation. In plain terms, it means leaving no important blockage behind.

The evidence is clear that leaving significant coronary disease untreated — because it is technically difficult or adds time to the operation — is associated with worse long-term outcomes. Patients whose disease is fully treated have lower rates of later heart attack, lower rates of repeat procedures, and better survival at five and ten years.

This is why the number of bypasses is, in some respects, a reflection of the surgeon’s commitment to doing the job properly. A patient who needs three vessels bypassed and receives three grafts has had their disease fully treated. A patient who receives only two grafts because the third vessel was technically challenging has been left with residual disease, and the consequences of that decision may not become apparent for years.

How we access the heart — and close it again

Figure 5

Inside the operative field

A view of the heart during bypass surgery, through the opening in the chest. The retractors on each side hold the chest open. The silver device in the middle gently holds a small area of the beating heart still while the graft is sewn on.

Illustration: E. Jeannes

For a typical triple bypass, the chest is opened through a midline incision called a median sternotomy (a controlled split of the breast bone). This gives the surgical team full access to all parts of the heart and allows us to harvest the internal mammary artery or arteries as grafts.

Traditionally, the split breast bone is brought back together at the end of the operation and held with stainless steel wires. One of the important improvements in recent years has been the use of titanium plates and screws to close the chest — a technique I have helped to develop. It is now recommended as part of modern Enhanced Recovery After Surgery (ERAS) guidelines, which are a set of practices designed to get patients home and back to normal life faster. With plate closure, patients need less pain relief, opioid use can often be avoided entirely, and the breast bone heals more securely.

When you meet your cardiac surgeon before your operation, it is entirely reasonable to ask: will all my blocked arteries be bypassed? What vessels are being grafted, and why? Are there any vessels that cannot be bypassed, and what does that mean for my outcome? And how will you close my chest — will you use plates and screws to help the breast bone heal?

Recovery — what the number means for you

The most important thing I can tell you about recovery from bypass surgery is this: the number of bypasses is one of the least important variables in how you will recover.

What matters far more is your age and baseline fitness, your heart muscle function going into the operation, whether you have diabetes, kidney disease, or lung disease, and whether this is your first heart surgery or a second operation after a previous one. A fit, active 60-year-old recovering from a triple bypass will almost always have a smoother and faster recovery than a sedentary 72-year-old recovering from a single bypass.

Recovery milestone	Typical timeframe
Breathing tube removed	Within hours of surgery in most patients
Out of intensive care	24–48 hours
Home from hospital	5–7 days in uncomplicated cases
Driving again	4–6 weeks — check with your surgeon (as little as 2 weeks if the sternum is closed with plates)
Return to light activity	4–6 weeks
Full recovery	6–12 weeks for most patients
Cardiac rehabilitation	Begins 4–6 weeks after surgery — strongly recommended

Cardiac rehabilitation — a structured program of supervised exercise, education, and psychological support — is one of the most important things you can do after bypass surgery, regardless of how many vessels were grafted. The evidence for its benefit in reducing repeat events, improving exercise capacity, and supporting return to a full life is overwhelming. I encourage every patient I operate on to attend.

A final word

Bypass surgery — whether single, double, triple, or quadruple — is one of the most studied and most successful operations in the history of medicine. More than a million procedures are performed worldwide each year, and the outcomes, for appropriately selected patients, are excellent.

The number of bypasses you need is determined by your anatomy — by the extent and location of your coronary disease, and by the surgical team’s commitment to treating it thoroughly. It is not a measure of how ill you are, how dangerous your operation will be, or how difficult your recovery will be. It is a description of thoroughness.

If you are facing bypass surgery, I hope this article has answered some of the questions that were forming in your mind when you first heard the number. The best thing you can do now is ask your cardiac surgeon to walk you through exactly what is planned — which vessels are being bypassed, what grafts will be used, and what treating all your disease thoroughly will mean for your long-term outlook. These are questions every cardiac surgeon expects to be asked, and they deserve a clear and complete answer.

Questions to ask your cardiac surgeon before bypass surgery

How many bypasses are planned, and which arteries are being grafted?
What grafts will be used — mammary artery, radial artery, or saphenous vein?
Will all my blocked arteries be bypassed — are there any vessels that cannot be treated?
What is my surgical risk based on my specific profile?
Will you close my chest with plates and screws?
What does recovery look like for someone with my age and health?
When can I start cardiac rehabilitation, and where should I go?
What medications will I need after surgery, and for how long?

Conditions

AI in Cardiology: What It Means for Your Heart, and What It Cannot Do

Aortic Stenosis: When the Heart’s Gateway Narrows

Patent Foramen Ovale (PFO): What the “Hole in the Heart” Finding Really Means

What is a Muscle Bridge?

White Coat Hypertension: When Your BP Spikes at the Doctor’s

Stroke and TIA Explained

Hypertrophic Cardiomyopathy: What HCM Actually Means

Stents or Bypass Surgery: How Your Heart Team Decides

Single, Double, Triple, Quadruple Bypass: What Does the Number Mean?

Does a Coffee a Day Keep AF at Bay?

What Is Atrial Fibrillation and How Does It Increase Stroke Risk?

Iron Deficiency and the Heart

SVT (Supraventricular Tachycardia) Explained: Causes and Treatment

Rheumatic Heart Disease: A Preventable Condition Affecting Millions

How to Lower Blood Pressure Naturally

An Isolated Inferior Q Wave on Your ECG: Why It’s Usually Nothing to Worry About

A Living Legend of Interventional Cardiology: Professor Patrick Serruys

What Do We Actually Mean by AI in Cardiology?

Where Is AI Already Making a Difference?

Stage 1: before you ever reach a specialist

Stage 2: investigating your heart

Stage 3: planning your procedure

Stage 4: in the procedure room

Stage 5: choosing your treatment

The quieter wins: less paperwork, more conversation

AI and Your Heart Team

What AI Cannot Do, and Why That Matters

What This Means for You as a Patient

Conclusion

References

Related Reading

What Is a PFO?

Normal Circulation Before Birth

When It Doesn’t Close

How Is a PFO Found?

Does It Actually Matter? The Context Question

The Incidental PFO, by Far the Most Common Situation

PFO and Cryptogenic Stroke, the Association That Matters

Migraine With Aura

What PFO Closure Involves

When in Doubt, Get Checked Out

Conclusion

Related Reading

What a Myocardial Bridge Actually Is

Why Most Bridges Cause No Trouble

When a Bridge Does Cause Symptoms

Why a Bridge Is Harder to Diagnose Than It Sounds

How Symptomatic Bridges Are Treated

Medication comes first

When an operation is considered

What the Latest Research Shows

The Bridge Is Rarely the Whole Story

When in Doubt, Get Checked Out

Conclusion

Related Reading

What White Coat Hypertension Actually Is

How Common Is It?

Why It Is Easy to Get Wrong

White Coat Versus Masked Hypertension

How It Is Diagnosed

Does It Need Treatment?

Getting an Accurate Reading at Home

When in Doubt, Get Checked Out

Conclusion

Related Reading

What Is a Stroke?

What Is a TIA?

Recognising the Signs: FAST

What Investigations Will I Have?

Brain imaging: MRI and CT

Carotid artery ultrasound

Heart rhythm monitoring: finding atrial fibrillation

When longer-term monitoring is needed

Echocardiogram: imaging the heart

Blood tests

Medications That Reduce the Risk of a Future Stroke

Blood-thinning medications

Blood pressure treatment

Statins and cholesterol management